Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. Two of Antabio’s programs have received Wellcome Trust Seeding Drug Discovery Awards to date: [i] a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections and [ii] a first-in-class inhibitor of Pseudomonas virulence to be co-administered with standard-of-care antibiotics for the long-term management of chronic respiratory infections. The company’s lead product is expected to enter the clinic in 2019 with a fast track to anticipated marketing approval. Antabio has built a best in class, international team of experts in the field and is currently seeking to raise additional funds to progress its pipeline up to the next value inflection point. Our company is also looking to in-license additional assets focused on Gram-negative antibiotic resistant therapies. Please visit www.antabio.com and follow us on Twitter @antabio
Location: France, Occitania, Labège
Employees: 11-50
Total raised: $63.53M
Founded date: 2009
Investors 5
| Date | Name | Website |
| - | Galia Gest... | galia-gest... |
| - | Turenne Ca... | turennecap... |
| - | AMR Action... | amractionf... |
| - | CARB-X | carb-x.org |
| - | Omnes Capi... | omnescapit... |
Funding Rounds 5
| Date | Series | Amount | Investors |
| 12.12.2023 | Series B | $27M | - |
| 02.01.2020 | - | $4.4M | CARB-X |
| 12.07.2018 | Series A | $14.62M | - |
| 17.10.2017 | Series A | $8.61M | - |
| 08.08.2017 | Grant | $8.9M | CARB-X |
Mentions in press and media 5
| Date | Title | Description |
| 12.12.2023 | Antabio Raises €25M in Series B Funding | Antabio, a Labège, France-based clinical stage biopharmaceutical company, raised €25M in Series B funding. The round saw participation from AMR Action Fund, the EIC Fund, BNP Paribas Développement, Relyens Innovation Santé / Turenne Capital... |
| 25.05.2023 | Antabio Announces First Subjects Dosed in Phase 1 Clinical Trial of MEM-ANT3310, a Highly Differentiated Antibiotic for Severe Hospital Infections | /EIN News/ -- MEM-ANT3310 has the potential to become the next standard of care for life-threatening infections due to its unique coverage including carbapenem-resistant Enterobacterales and Acinetobacter baumannii Labège, France - May 25, ... |
| 02.01.2020 | Top tech startup news for today, Thursday, January 2, 2020 – Google, Microsoft, Bosch, Trifo, BlueConic, Mobike, Antabio | Happy New Year! Welcome to 2010. Below is our first top startup new stories of the year 2020. Germany’s Bosch to offer lower-cost sensors for self-driving cars. German automotive supplier Robert Bosch announced Thursday it has developed a ... |
| 02.01.2020 | French biotech startup Antabio receives $4.4 million from CARB-X to further development of new treatment for cystic fibrosis patients | Antabion, a Labege, France-based biotech startup announced today it has been awarded up to $4.4 million in a second tranche funding from CARB-X, a global non-profit partnership dedicated to tackling the global rising threat of drug-resistan... |
| 12.07.2018 | Biopharma Company Antabio Raises Additional €5.2M; Closes €12.5M Series A | Antabio SAS, a Labège, France-based biopharmaceutical company developing novel antibacterial treatments, extended its Series A financing round with an additional €5.2m. The additional funding was subscribed by investment funds Omnes, BNP Pa... |